Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more
Stoke Therapeutics Inc (STOK) - Total Liabilities
Latest total liabilities as of September 2025: $52.16 Million USD
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has total liabilities worth $52.16 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Stoke Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Stoke Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Stoke Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Stoke Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Greenbrier Companies Inc
F:G90
|
Germany | €2.56 Billion |
|
IRSA Inversiones Y Representaciones
NYSE:IRS
|
USA | $1.27 Trillion |
|
Sparebanken Vest
OL:SVEG
|
Norway | Nkr319.85 Billion |
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
China | CN¥3.70 Billion |
|
Phu Nhuan Jewelry JSC
VN:PNJ
|
Vietnam | ₫6.89 Trillion |
|
Rendong Holdings Co Ltd
SHE:002647
|
China | CN¥4.46 Billion |
|
Guobo Electronics Co. Ltd. A
SHG:688375
|
China | CN¥1.47 Billion |
|
AEORF
PINK:AEORF
|
USA | $207.34 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Stoke Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stoke Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stoke Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Stoke Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.53 Million | -38.16% |
| 2023-12-31 | $68.78 Million | -3.43% |
| 2022-12-31 | $71.22 Million | +237.72% |
| 2021-12-31 | $21.09 Million | +78.00% |
| 2020-12-31 | $11.85 Million | +174.11% |
| 2019-12-31 | $4.32 Million | +74.91% |
| 2018-12-31 | $2.47 Million | -33.77% |
| 2017-12-31 | $3.73 Million | -- |